## CBD DROPS CURCUMIN 5%



Ingredients: CAPRYLIC/CAPRIC TRIGLYCERIDE, OLEA EUROPAEA FRUIT OIL, CANNABIS SATIVA BIOMASS EXTRACT, CURCUMA LONGA RHIZOME EXTRACT, PIPER NIGRUM FRUIT EXTRACT



HEMP EXTRACT Cannabis sativa L.



OLIVE OIL Olea europaea



TURMERIC EXTRACT

Curcuma longa



BLACK PEPPER EXTRACT
Piper nigrum





## **CERTIFICATE OF ANALYSIS No.: 2022-9280**

## **CLIENT**


Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \*

CBD DROPS CURCUMIN 5% - olive oil

\* Information provided by the client.





| Sample condition: | SUITABLE       | Work order:  | 2022-106658    | Sample received:   | 22/06/2022    |
|-------------------|----------------|--------------|----------------|--------------------|---------------|
| Sample ID:        | 2225018        | Analysis ID: | 2022_143       | Start of analysis: | 22/06/2022    |
| Sample type:      | Viscous liquid | Method ID:   | PHL_RPC_12C    | End of analysis:   | 23/06/2022    |
| Batch No.: *      | DR05022173C    | Method SOP:  | MET-LAB-003-02 | Analyst:           | Karmen Korbar |

| CANNABINOID PROFILE  |                                   | Concentration<br>[% w/w] | Expanded<br>uncertainty<br>[% w/w] | Graphic presentation of relative cannabinoid concentration |  |
|----------------------|-----------------------------------|--------------------------|------------------------------------|--|--|
| CBDV                 | - Cannabidivarin                  | 0.359                    | 0.065                              |  |  |
| CBDA                 | - Cannabidiolic acid              | 1.908                    | 0.095                              |  |  |
| CBGA                 | - Cannabigerolic acid             | 0.041                    | 0.012                              |  |  |
| CBG                  | - Cannabigerol                    | 0.054                    | 0.016                              | l  |  |
| CBD                  | - Cannabidiol                     | 3.33                     | 0.17                               |  |  |
| HCV                  | - Tetrahydrocannabivarin          | 0.116                    | 0.019                              | I  |  |
| BN                   | - Cannabinol                      | < LOQ                    | n/a                                |  |  |
| <sup>9</sup> -THC    | - Δ-9-Tetrahydrocannabinol        | 0.053                    | 0.012                              | L  |  |
| <sup>8</sup> -THC    | - Δ-8-Tetrahydrocannabinol        | < LOQ                    | n/a                                |  |  |
| BL                   | - Cannabicyclol                   | < LOQ                    | n/a                                |  |  |
| ВС                   | - Cannabichromene                 | 0.0395                   | 0.0087                             | <u> </u>   |  |
| ∆ <sup>9</sup> -THCA | - Δ-9-Tetrahydrocannabinolic acid | 0.0368                   | 0.0081                             |  |  |
| ВЕ                   | - Cannabielsoin                   | < LOQ#                   | n/a                                |  |  |
| BNV                  | - Cannabivarin                    | < LOQ#                   | n/a                                |  |  |
| ВСА                  | - Cannabichromenic acid           | 0.068#                   | 0.016                              | <u> </u>   |  |
| ВТ                   | - Cannabicitran                   | < LOQ#                   | n/a                                |  |  |

 $\underline{\text{Units and abbreviations}}: \text{$W$/W$} = \text{weight percent}, < \textbf{LOQ} = \text{below the limit of quantitation (0.03 \% w/w)}, \ \textbf{ND} = \text{not detected}, \ \textbf{n/a} = \text{not available}.$ 

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

| Date issued:       | Approved by:                  | Authorized by:           |
|--------------------|-------------------------------|--------------------------|
|                    | )                             | Jany Fatz                |
| 23/06/2022         | Muyn                          |                          |
|                    | mag. Mayko Dragan             | dr. Boštjan Jančar       |
|                    | Analytical Laboratory Manager | Chief Technology Officer |
| End of Certificate |                               |                          |

PharmaHemp d.o.o. | Cesta v Gorice 8 | 1000 Ljubljana | Slovenia | info@pharma-lab.eu | https://pharma-lab.eu